Watch TECH. Know when insiders buy.
One email the day a filing lands. Free.
TECH
BIO-TECHNE Corp
72.64
+0.06 +0.08%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
74
PASS · shorts 74
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $11.4BP/E 63.2DIV YIELD —FCF YIELD 2.31%REV TTM $1.2B −0.4%NET INCOME $181.9M +147.8%NET CASH $64.7M52W 43.30 – 72.64SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2026 · Jun 30derived | $321.2M | +1.3% | 65.8% | $74.3M | $54.6M | — | 0.35 | $95.4M | $8.5M | $86.9M | Aug 24 |
| Q3 2026 · Mar 31 | $311.4M | −1.5% | 66.9% | $75.5M | $51M | +126.0% | 0.32 | $86.7M | $9.1M | $77.6M | May 6 |
| Q2 2026 · Dec 31 | $295.9M | −0.4% | 64.6% | $54.5M | $38M | +8.9% | 0.24 | $82.4M | $5.9M | $76.5M | May 6 |
| Q1 2026 · Sep 30 | $286.6M | −1.0% | 65.6% | $47.7M | $38.2M | +13.6% | 0.24 | $27.6M | $5.4M | $22.2M | May 6 |
| Q4 2025 · Jun 30derived | $317M | +3.5% | 62.7% | −$23.9M | −$17.7M | −143.6% | -0.11 | $98.2M | $4.9M | $93.3M | Aug 24 |
| Q3 2025 · Mar 31 | $316.2M | +4.2% | 67.9% | $38.7M | $22.6M | −54.0% | 0.14 | $41.1M | $10.1M | $31M | May 6 |
| Q2 2025 · Dec 31 | $297M | +9.0% | 65.3% | $47.4M | $34.9M | +27.0% | 0.22 | $84.3M | $6.8M | $77.5M | May 6 |
| Q1 2025 · Sep 30 | $289.5M | +4.5% | 63.2% | $40M | $33.6M | −34.1% | 0.21 | $63.9M | $9.2M | $54.7M | May 6 |
| Q4 2024 · Jun 30derived | $306.1M | — | 66.4% | $45.8M | $40.6M | — | 0.26 | $75.5M | $18M | $57.5M | Aug 24 |
| Q3 2024 · Mar 31 | $303.4M | — | 67.4% | $67M | $49.1M | — | 0.31 | $81M | $16.4M | $64.5M | May 8 |
| Q2 2024 · Dec 31 | $272.6M | — | 64.8% | $38M | $27.5M | — | 0.17 | $83.1M | $14.9M | $68.3M | Feb 6 |
| Q1 2024 · Sep 30 | $276.9M | — | 66.9% | $55.9M | $51M | — | 0.31 | $59.4M | $13.6M | $45.8M | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Jun 30 | $1.2B | 65.8% | $251.9M | $181.9M | 15.0% | 1.16 | $292.1M | $28.9M | $263.2M | $41.7M | $49.9M |
| FY2025 · to Jun 30 | $1.2B | 64.8% | $102.3M | $73.4M | 6.0% | 0.46 | $287.6M | $31M | $256.6M | $275.7M | $50.4M |
| FY2024 · to Jun 30 | $1.2B | 66.4% | $206.7M | $168.1M | 14.5% | 1.05 | $299M | $62.9M | $236.1M | $80M | $50.4M |
| FY2023 · to Jun 30 | $1.1B | 67.7% | $298.9M | $285.3M | 25.1% | 1.76 | $254.4M | $38.2M | $216.1M | $19.6M | $50.3M |
| FY2022 · to Jun 30 | $1.1B | 68.4% | $296.6M | $272.1M | 24.6% | 1.66 | $325.3M | $44.9M | $280.4M | $160.9M | $50.2M |
| FY2021 · to Jun 30 | $931M | 68.0% | $237.3M | $140.4M | 15.1% | 0.87 | $352.2M | $44.3M | $307.9M | $43.2M | $49.6M |
Every number comes from BIO-TECHNE Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.